Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.

Deguchi T, Watanabe N, Kurihara A, Igeta K, Ikenaga H, Fusegawa K, Suzuki N, Murata S, Hirouchi M, Furuta Y, Iwasaki M, Okazaki O, Izumi T.

Drug Metab Dispos. 2011 May;39(5):820-9. doi: 10.1124/dmd.110.037457. Epub 2011 Jan 31.

2.

Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.

Furukawa T, Nakamori F, Tetsuka K, Naritomi Y, Moriguchi H, Yamano K, Terashita S, Teramura T.

Drug Metab Pharmacokinet. 2012;27(2):171-80. Epub 2011 Oct 4.

3.

Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.

Sinha VK, Vaarties K, De Buck SS, Fenu LA, Nijsen M, Gilissen RA, Sanderson W, Van Uytsel K, Hoeben E, Van Peer A, Mackie CE, Smit JW.

Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000.

PMID:
21456631
4.

Predicting oral clearance in humans: how close can we get with allometry?

Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE.

Clin Pharmacokinet. 2008;47(1):35-45.

PMID:
18076217
5.

Species differences in distribution and prediction of human V(ss) from preclinical data.

Berry LM, Li C, Zhao Z.

Drug Metab Dispos. 2011 Nov;39(11):2103-16. doi: 10.1124/dmd.111.040766. Epub 2011 Aug 18.

6.

Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach.

Gilibili RR, Mullangi R, Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2011 Jun;36(2):87-93. doi: 10.1007/s13318-011-0029-x. Epub 2011 Mar 5.

PMID:
21380569
7.

Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.

Yang Z, Zadjura L, D'Arienzo C, Marino A, Santone K, Klunk L, Greene D, Lin PF, Colonno R, Wang T, Meanwell N, Hansel S.

Biopharm Drug Dispos. 2005 Dec;26(9):387-402.

PMID:
16142720
8.
9.

Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.

Bae SK, Lee SJ, Kim YG, Kim SH, Kim JW, Kim T, Lee MG.

Biopharm Drug Dispos. 2005 Apr;26(3):99-115.

PMID:
15723427
10.

Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.

Pavankuamr VV, Vinu CA, Mullangi R, Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2007 Jan-Mar;32(1):29-37.

PMID:
17479541
11.

Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.

Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A.

Xenobiotica. 2006 Jul;36(7):567-80.

PMID:
16864504
12.

Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.

Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A.

Drug Metab Dispos. 2009 Jan;37(1):82-9. doi: 10.1124/dmd.108.023853. Epub 2008 Oct 2.

13.

Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.

Nakamori F, Naritomi Y, Hosoya K, Moriguchi H, Tetsuka K, Furukawa T, Kadono K, Yamano K, Terashita S, Teramura T.

Drug Metab Dispos. 2012 Sep;40(9):1771-7. doi: 10.1124/dmd.112.045476. Epub 2012 Jun 8.

14.

Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.

J Clin Pharmacol. 2009 May;49(5):513-33. doi: 10.1177/0091270009333209. Epub 2009 Mar 19.

PMID:
19299532
15.

Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.

Kumar V, Schuck EL, Pelletier RD, Farah N, Condon KB, Ye M, Rowbottom C, King BM, Zhang ZY, Saxton PL, Wong YN.

Cancer Chemother Pharmacol. 2012 Jan;69(1):229-37. doi: 10.1007/s00280-011-1687-8. Epub 2011 Jun 23.

PMID:
21698359
16.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3.

PMID:
21541938
17.

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.

Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH.

J Antimicrob Chemother. 1999 May;43 Suppl B:69-76.

PMID:
10382878
18.
19.

Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Cubitt HE, Houston JB, Galetin A.

Pharm Res. 2009 May;26(5):1073-83. doi: 10.1007/s11095-008-9823-9. Epub 2009 Jan 31.

PMID:
19184618
20.

Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.

Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC.

J Pharm Pharmacol. 1996 Jun;48(6):573-7.

PMID:
8832489

Supplemental Content

Support Center